Deksmedetomidin

Deksmedetomidin
IUPAC ime
	(S)-4-[1-(2,3-dimetilfenil)etil]-3H-imidazol
Klinički podaci
Prodajno ime	Precedex, Dexdor
Drugs.com	Monografija
Kategorija trudnoće	US: C (Mogući rizik) ; ;
Način primene	Intravenozna infuzija
Pravni status
Pravni status	US: ℞-only ;
Farmakokinetički podaci
Vezivanje proteina	94%
Metabolizam	Skoro potpuni hepatički metabolizam do neaktivnog metabolita
Poluvreme eliminacije	2 sata
Izlučivanje	Urinarno
Identifikatori
CAS broj	113775-47-6
ATC kod	N05CM18 (WHO)
PubChem	CID 68602
DrugBank	DB00633
ChemSpider	4470605
UNII	67VB76HONO
KEGG	D00514
ChEBI	CHEBI:4466
ChEMBL	CHEMBL778
Hemijski podaci
Formula	C13H16N2
Molarna masa	200,28 g/mol
	SMILES n1cc(nc1)[C@H](c2c(c(ccc2)C)C)C; ;
	InChI InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1 ; Key:CUHVIMMYOGQXCV-NSHDSACASA-N ;

Deksmedetomidin (Precedeks, Deksdor) je sedativ koji koristi za intezivnu negu i anesteziju. On je relativno neobičan po tome što omogućava sedaciju bez izazivanja respiratorne depresije. Poput klonidina, on je agonist α₂-adrenergičkog receptora u mozgu.^[1] On je S-enantiomer medetomidina,^[2] koji se koristi u veterini.

Reference

^ Cormack JR, Orme RM, Costello TG (2005). „The role of alpha2-agonists in neurosurgery”. Journal of Clinical Neuroscience. 12 (4): 375—8. PMID 15925765. doi:10.1016/j.jocn.2004.06.008.
^ PubChem 5311068

Literatura

„Dosing Guidelines for Precedex” (PDF). Архивирано из оригинала (PDF) 15. 07. 2011. г. Приступљено 21. 11. 2010.
Jackson KC, Wang Z, Wohlt P, Fine PG (2006). „Dexmedetomidine a novel analgesic with palliative medicine potential”. J Pain and Palliative Care Pharmacotherapy. 20 (2): 23—7. PMID 16702133. doi:10.1080/J354v20n02_05.
Menon DV, Wang Z, Fadel PJ, Arbique D, Leonard D, Li JL, Victor RG, Vongpatanasin W (2007). „Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans”. J Am Coll Cardiol. 50 (7): 626—33. PMID 17692748. doi:10.1016/j.jacc.2007.03.060.
O'Connor, M; Bucknall, T; Manias, E (2009). „Sedation Management in Australian and New Zealand Intensive Care Units: Doctors' and Nurses' Practices and Opinions”. Am J Crit Care. 19 (3): 285—95. PMID 19770414. doi:10.4037/ajcc2009541.
Pandharipande, PP; Pun, BT; Herr, DL; Maze, M; Girard, TD; Miller, RR; Shintani, AK; Thompson, JL; Jackson, JC (2007). „Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial”. JAMA. 298 (22): 2644—53. PMID 18073360. doi:10.1001/jama.298.22.2644.
Paris A, Tonner PH (2005). „Dexmedetomidine in anaesthesia”. Current Opinion in Anaesthesiology. 18 (4): 412—8. PMID 16534267. doi:10.1097/01.aco.0000174958.05383.d5.
Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG (2009). „Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients: A Randomized Trial”. JAMA. 301 (5): 489—99. PMID 19188334. doi:10.1001/jama.2009.56.
Dasta JF; Kane-Gill SL; Pencina M; et al. (2010). „A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit”. Crit Care Med. 38 (2): 497—503. PMID 19789442.
Wunsch H. (2011). „Weighing the Costs and Benefits of a Sedative”. JAMA. 307 (11): 1195—1197. doi:10.1001/jama.2012.319. Архивирано из оригинала 27. 03. 2012. г. Приступљено 16. 08. 2012.

Spoljašnje veze

Website of Precedex

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[Cormack2005-1] Cormack JR, Orme RM, Costello TG (2005). „The role of alpha2-agonists in neurosurgery”. Journal of Clinical Neuroscience. 12 (4): 375—8. PMID 15925765. doi:10.1016/j.jocn.2004.06.008.

[PubChem-2] PubChem 5311068

[1]

[2]